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BACKGROUND
Improvements are being made to meet the ever-increasing demands and expectations in 
health services. It has become the health policy of all states to provide these services in an 
equal, timely, quality, and effective manner to all [1]. The purpose of health policies is to en-
sure that the system is sustainable [2] and manageable [3].
The main factors are the increase in the general population, the elderly population, and in 
chronic diseases, the widening of health-insurance coverage, and the change in the profile of 
diseases which are leading to changes in the health sector [4]. According to perceived ben-
efits, individuals, businesses, and the state face difficult decisions on the allocation of health 
resources against the high costs of some interventions. High-priced drugs place considerable 
pressure on government budgets [5]. In the Organization of Economic Co-operation and De-
velopment (OECD) countries, one out of every five dollars for health is spent on medicines 
[6]. Considering economic concerns, states determined which intervention provides the high-
est value while keeping health costs under control [7].
The duties of the state and politicians include ensuring that people live healthily and have 
access to drugs [8]. Access to drugs is a concern not only for governments but also for phar-
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ABSTRACT
BACKGROUND: Reimbursement agencies are increasingly adopting innovative reimbursement approaches for new and 
expensive technologies. Social Security Institution (SSI), Turkey`s reimbursement agency, established the Alternative Re-
imbursement Commission (ARC) on February 10, 2016. This study aimed to understand the implementations of market 
access agreements in recent years in Turkey.
METHODS: Decisions of the Health Services Pricing Commission published in the official gazette , and information from 
the Turkey Pharmaceuticals and Medical Devices Agency, the Abroad Drug List, Health Implementation Communique 
published by SSI with additional lists, such as the Annex-4A List of Reimbursed Medicines and the Annex-4C Abroad Drug 
Price List, were used. The data was transferred to Windows Office Excel files, and a descriptive analysis was conducted and 
evaluated by two market access experts.
RESULTS: There were 57 drugs included in the coverage of reimbursement with alternative reimbursement since the ap-
plication was started in Turkey. 35 of them were added to Annex-4A and 22 of them to Annex-4C. Furthermore, 45.6% of 
the drugs had an Anatomic Therapeutic Chemical Classification (ATC) code of l-antineoplastic and immunomodulating 
agents, 28% were orphan drugs, 44 of them had a confidential discount rate, and financial-based agreement models were 
preferred for nearly all agreements. 
CONCLUSIONS: Turkey has been implementing market access agreements since mid-2016. In the past 3 years, 57 drugs 
have been covered for reimbursement under the new implementation. Further analysis should be conducted to understand 
the decision-making process involved.
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cess of the drug to patients, the supply of the required drug to the market, the ability of pa-
tients to afford drug prices, and the proven effectiveness of the drug [10].
The rapid developments in the health sector have enabled more effective and successful 
treatments for several diseases; however, the high research and development (R&D) costs 
of the technologies they contain make it difficult for the paying institution and the patient in 
need [11]. Regarding the introduction and use of new health technologies, health technology 
assessment (HTA) is a systematic, transparent, and meticulous scientific approach that evalu-
ates the clinical, economic, organizational, social, legal, and ethical effects of present and new 
technologies, and it provides information to decision makers and clinicians [12].
MARKET ACCESS
The concept of market access was first developed by the World Trade Organization 
(WTO), and it includes the opening of markets to trade, increasing transparency in interna-
tional trade, reciprocity, and a lack of discrimination [13]. Market access, including licens-
ing, pricing, and reimbursement processes in general, is a set of processes that ensure that a 
product is quickly and sustainably accessed by all eligible patients in need of that product at 
an affordable price to ensure  maximum reimbursement and minimum restriction in financing 
[14,15]. The introduction of the product into the market is defined as the opening of countries’ 
markets to new services and products. The World Health Organization (WHO) emphasizes 
that access to health care is a human right. Therefore, access to medicine or a health product 
is a human right [16].
Market access agreements are a form of guarantee offered by the pharmaceutical company 
for new and costly products [17]. Market access agreements can be regarded as sharing risks 
foreseen for a drug in terms of cost-effectiveness and budgetary impact analysis [18] for both 
the manufacturer and the reimbursement agency under the provisions of the contract with the 
pharmaceutical company. With these agreements, both parties aim to eliminate uncertainty 
from their perspective [16]. Furthermore, risk-sharing agreements are crucial to eliminate the 
risk caused by exchange rate fluctuations between any two countries [19].
How long will market access have different meanings for the pharmaceutical company, 
clinicians, patient, and paying institutions? The more quickly the pharmaceutical company 
provides access to the market, the more successful and the more profitable it will be. Clini-
cians want the ability to prescribe different treatment options to the patient, and the patient 
wants to access new technologies as quickly as possible. The reimbursement institution has 
to consider total drug expenditures, its proportion in health expenditures, the balances in the 
market, and the sustainability factor while providing the patient with the drug he or she needs. 
To make a decision, the evidence must be sufficiently convincing and prompt. Furthermore, 
the uncertainties should be tolerated, and the value of the drug should be trusted.
Research has demonstrated that more than half of an individual’s health expenditure is 
spent after retirement. Therefore, it can be said that market access will become a crucial issue 
in coming years [20].
Turkey will soon become the fastest-aging country in the OECD by 2050 [21]. Such a 
development provides a challenge for the public and an opportunity for pharmaceutical com-
panies [20].
Market access agreements may occur in a variety of ways, such as price-volume agree-
ments, outcome-guaranteed programs, and proof-of-evidence payment. These agreements can 
be defined as “risk-sharing agreements,” “performance-based agreements,” “patient access 
programs,” and “managed input agreements” [22].
Risk-sharing agreements can be divided into two main classes: finance-based models and 
outcome- or performance-based models [23] (Figure 1). The model to be applied should be 
decided according to the need of the payer and the suitability of the country’s infrastructure. In 
general, performance-based models are used in conditions of clinical uncertainty, and finance-
based models are used in conditions that involve uncertainties about the budget [24].
Depending on the type of agreement, pharmaceutical companies either offer discounts on 
sales volume (price-volume agreements) or apply total or partial reimbursements when treatments 
are not as effective and safe as initially believed (payment agreements for performance) [25].
Performance-Based Agreements
Performance-based agreements are defined as agreements between the healthcare provider 
and medical product manufacturers in which price, level, or quality of reimbursement depends 
on future clinical or intermediate termination point measurements of the patient’s quality of 
life or life decency. It is based on predefined outputs or new evidence, usually clinical [26]. 
Such agreements regulate the reimbursement of the product on designated patients within a 
given period, according to their established health outcomes [27]. In these models, an agree-
ment is reached between the company and the payer to conduct a program on evidence or data 
collection. The program is initiated or requested by the payer. The objective is to reduce the 
uncertainties associated with the long-term efficacy and the cost-effectiveness of the drug [24].
Conditional refund
Conditional refund is the preferred model for medicinal products that are new but not 
available for reimbursement due to the lack of existing data or real-life data. Such agreements 
create opportunities for real-life data for both reimbursement institutions and pharmaceuti-
cal companies while ensuring that companies do not lose time in market access [27]. These 
agreements include the reimbursement of a portion of the cost spent by the manufacturer if 
the drug does not achieve the desired result in the appropriate population [28]. Conditional 
reimbursement models are divided into two subclasses: evidence-based reimbursement and 
conditional treatment continuity.
Evidence-based reimbursement includes reimbursement of treatment or technology that 
requires data collection through clinical research or registration with the participation of the 
manufacturer to determine the effectiveness of specific promising technologies [29]. It is di-
vided in reimbursement within the scope of the clinical study, which refers to reimburse de-
pending on the provided clinical data from the manufacturer supported clinical trials [27], and 
reimbursement based on additional clinical data collection, in which, in case of insufficient 
clinical data, the reimbursement institution includes the product in the scope of reimburse-
ment provided that the manufacturer collects additional clinical data [28].
Reimbursement within the Scope of Conditional Treatment Continuity is reimbursement 
for ongoing treatment in patients who have achieved the targeted clinical effect. Furthermore, 
such programs may include full or partial reimbursements for patients who did not achieve 
the targeted effect [27]. It is a model in which the payer provides temporary funding to collect 
the information necessary to reduce existing uncertainties regarding a coverage decision. The 
disadvantage of these agreements is that the drug does not provide the benefit of the clinical 
trial in real life due to errors in patient selection [30].
Performance-based reimbursement
Performance-based reimbursement is based only on real-life clinical results. The pharma-
ceutical company agrees to provide a certain number of products free of charge based on data 
from clinical trials. For patients who benefit at the end of the process, the drug is included in 
reimbursement. For patients with no benefit, different treatment options are investigated [27]. 
Performance-based reimbursement is divided into two categories: result guaranteed reim-
bursement and reimbursement by treatment process.Figure 1. Risk Sharing Agreements. Modified from [23]
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collection. The program is initiated or requested by the payer. The objective is to reduce the 
uncertainties associated with the long-term efficacy and the cost-effectiveness of the drug [24].
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cal companies while ensuring that companies do not lose time in market access [27]. These 
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the drug does not achieve the desired result in the appropriate population [28]. Conditional 
reimbursement models are divided into two subclasses: evidence-based reimbursement and 
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Evidence-based reimbursement includes reimbursement of treatment or technology that 
requires data collection through clinical research or registration with the participation of the 
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reimbursement based on additional clinical data collection, in which, in case of insufficient 
clinical data, the reimbursement institution includes the product in the scope of reimburse-
ment provided that the manufacturer collects additional clinical data [28].
Reimbursement within the Scope of Conditional Treatment Continuity is reimbursement 
for ongoing treatment in patients who have achieved the targeted clinical effect. Furthermore, 
such programs may include full or partial reimbursements for patients who did not achieve 
the targeted effect [27]. It is a model in which the payer provides temporary funding to collect 
the information necessary to reduce existing uncertainties regarding a coverage decision. The 
disadvantage of these agreements is that the drug does not provide the benefit of the clinical 
trial in real life due to errors in patient selection [30].
Performance-based reimbursement
Performance-based reimbursement is based only on real-life clinical results. The pharma-
ceutical company agrees to provide a certain number of products free of charge based on data 
from clinical trials. For patients who benefit at the end of the process, the drug is included in 
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Performance-based reimbursement is divided into two categories: result guaranteed reim-
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In the result-based reimbursement pharmaceutical company takes a refund or a discount 
to the paying institution for the patient group when a reimbursed drug does not provide any 
benefit. It is a model where the price is directly linked to a specific outcome for each patient. 
Regarding the agreement in the treatment process, according to the evaluations made at the 
intermediate endpoint or clinical endpoint, a certain portion of the costs of the patients who 
do not respond to treatment are paid by the company to the paying institution [28]. The reim-
bursement by treatment process occurs when the company selects patients using biological 
markers, such as genetic testing, under clinical treatment guidelines [27].
Financial Based Agreements
These types of agreements are used to manage financial risks due to uncertainty in estimat-
ing general use or cost or to reduce payment risk from using drugs off the restricted list [31]. 
Financial contracts are usually discount-based and have a direct impact on the net price. Since 
the aim is not to prove the effectiveness of the drug but to eliminate financial uncertainty, there 
is no need to collect patient data [32].
Patient-Level Agreements
Patient-level agreements model is defined as setting different prices for a particular tech-
nology in different patients. However, the price level is not only determined by the patient out-
comes but is also linked to other treatment-related factors [28]. It is divided in firm-supported 
initial dose and individual use limit agreements. Firm-supported initial agreements are used 
where the cost is borne by the manufacturer, and the total cost for the paying institution is 
reduced, regardless of success or failure, usually for patients in the initial phase of treatment. 
The list at the beginning of treatment includes patients receiving technology for a price dif-
ferent from the price [32]. Unlike the conditional treatment continuity model, there is no con-
sensus that treatment will remain within reimbursement if patients achieve a target effect [28]. 
In the Individual use limit model, also called the individual volume model, the total cost of 
drugs to be covered by the paying institution per patient is predetermined. If it is determined 
that the patient requires further treatment after an agreed period of treatment, some or all of 
the amount exceeded is covered by the manufacturer [28].
Population-level agreements
Population-level agreements are characterized by effective prices determined at the 
health-system level instead of at the level of the individual patient [33]. They are divided 
in price-based and price-volume agreements. Price-based agreements include the discount 
between the producer and the buyer as a result of bargaining the product per box at the list 
price. However, examples of such agreements are limited as a result of global reference 
pricing, where drug pricing in one country is linked to the price in another country [28]. As 
a result, such agreements are made in the form of confidential discounts and are not pub-
lished because pharmaceutical companies are afraid of a price war for their products [33]. 
Confidentiality of the agreements gives the advantage to the reimbursement institution in 
terms of negotiations for other drugs that are equivalent to the drug and to the company in 
terms of competition [34]. Price-volume agreements are made against the risk of the product 
exceeding the estimated number of patients after access to the market is approved and an 
unexpected increase in drug expenditures. The pharmaceutical company makes a certain 
price reduction or exceeds the expected payer to the payer when the estimated patient or 
box sales exceed. In the implementation of this model, it is important to follow the drug 
meticulously [32].
Market Access in Turkey
In Turkey, depending on the drug licensing and pricing activity, monitoring and manage-
ment of the Ministry of Health Turkey Pharmaceuticals and Medical Devices Agency (TP-
MDA) is implemented through the licensing application by pharmaceutical manufacturers. 
The “Human Medicinal Products Licensing Regulation” is implemented by TPMDA. The 
drug reimbursement is made by the Social Security Institution (SSI), which is affiliated to 
the Ministry of Family, Labor, and Social Services [14,24]. The most important criteria for 
reimbursement are clinical effectiveness, safety, quality, cost-effectiveness, and affordability 
[16]. With its reimbursement policies, SSI provides medicines to people under its system and 
takes measures to ensure that pharmaceutical expenditures do not exceed their budgets. As a 
result, in 2009 in Turkey, government requested cost-effectiveness and budget impact analysis 
from the innovative pharmaceutical products. This has required pharmaceutical companies to 
scientifically prove to the public that their products are cost-effective [20].
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The difference between income and expense for SSI was determined as 20.656 Million 
TL in 2016. To cover the budget deficits, the SSI has taken certain measures to reduce health 
expenditures. In 2014, rational drug use was introduced. For the same purpose, due to the 
implementation of the global budget between 2010 and 2012, the public drug budget was ex-
ceeded, and drug pricing and public discount rates were changed and restrictions were made 
on drug expenditures [12]. To this end, on February 10, 2016, the Alternative Reimbursement 
Commission (ARC), the Drug Reimbursement Commission, and the Medical and Economic 
Reimbursement Commission were published in the official newspaper as subcommissions of 
the Health Services Pricing Commission (HSPC) [35].
The main purpose of this study was to understand the market access agreements scheme 
in Turkey.
METHODS
In this study, with the aim to report the market access agreements in Turkey, relevant leg-
islation, announcements, official publications, and reports were examined. The official sites of 
the SSI, TPMDA, the official gazette, the Ministry of Health, the Association of Investigative 
pharmaceutical companies (AIPC), the Pharmaceutical industry employers’ union (PIEU), 
and Turkish Pharmacists’ Association (TPA) were used to examine the activities implemented 
and data included in Turkey since 2016 for the related legislation.
Data were taken from the current TPMDA International Drug List dated January 02, 2019, 
SSI SUT supplementary lists, Annex-4A List Reimbursement Medicines, and the Annex 4c 
International Drug Price List. The investigation also included the decisions of HSPC pub-
lished in the official gazette between October 02, 2016 and January 02, 2019 (Access Date: 
May 5, 2019).
In the current study, content analysis, a qualitative research method, was used to examine 
the drugs covered by alternative reimbursement. The alternative reimbursement published in 
the HSPC decisions, the SSI Health Application Communique (HAC) annex lists, which are 
included in the list of medicines to be paid in Annex-4A and the Annex-4C International Drug 
Price List, including the year, price, discount rate, Anatomic Therapeutic Chemical Classifica-
tion (ATC) code, disease, generic drug, and reimbursement required data were reached for the 
analysis. The obtained data were transferred to Windows Office Excel files.
RESULTS
The first market access agreement has been signed for the products used in the treatment 
of Hepatitis C. The products have received reimbursement approval since June 18, 2016. The 
public discount rates have not been published for these products, and confidential discounting 
has been initiated. It was the first time the public discount rates kept confidential in Turkey. 
Currently, there are 57 drugs included in the alternative reimbursement process (as of May 21, 
2019). Ten of these drugs were included in alternative reimbursement in 2016, 13 in 2017, 24 
in 2018, and 10 in 2019.
Of the 57 medicines covered by ARC 
agreements, 35 were added to the List of 
Reimbursed Medicines for 4A and 22 of 
them were added to the 4C international 
drug price list. Of the drugs listed in 4A, 
32 were original and three were generic 
products. There were 16 orphan drugs 
within the scope of ARC. Eight of these 
drugs were in the list of drugs to be paid 
for 4A price, and 8 were in the 4C in-
ternational drug price list. There were no 
restrictions on reimbursement in 11 of 
the drugs in the 4A List of Reimbursed 
Medicines, whereas 24 had restrictions. 
Eighteen of the products in the 4C Inter-
national Drug Price List had restrictions.
L-Antineoplastic and immunomodu-
latory agents constitute the most com-








L Antineoplastic and 
Immunomodulating Agents
26 21 5
A Gastrointestinal Canal 
and Metabolism
10 3 7
J Systemic Anti-infective 5 5 -
M Musculoskeletal System 4 1 3
N Nervous system 3 2 1
V Various 3 1 2
D Drugs Used in Dermatology 2 1 1
R Respiratory system 1 1 -
C Cardiovascular System 1 - 1
B Blood and Blood Making Organs 1 - 1
N/A 1 - 1
Total 57 35 22
Table I. Alternative Reimbursement Drugs by ATC
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ered by alternative reimbursement. This group was typically related to cancer and immune 
system diseases (Table I). Oncology drugs constituted the majority of the drugs that were 
reimbursed by the ARC. (Table II).
The reimbursement discount rates of 44 (77.19%) products were not published. A confi-
dential discount application was made for these products. Mandatory reimbursement discount 
of 41% on 14.03% of 57 products, other reimbursement discounts of 31% on 1.75%, 29% on 
1.75%, 28% on 1.75%, 12% on 1.75%, and 10% on 1.75% were applied. Due to the applied 
reference price practice in Turkey, products in the other countries may be affected by the refer-
ence price changes in Turkey. To protect against this situation, confidential discounts are ap-
plied between the company and the pay-
ing institution, and the public prices of 
the products are kept confidential or high-
er in price lists (Figure 2).
The average reimbursement discount 
rate of the products whose discount rates 
were announced was 33.69%. Of the 
products with published discount rates, 
a 41% discount was applied to the list 
price in 8 of 13 products. All 13 prod-
ucts were added to the Annex-4A List of 
Reimbursed Medicines and have access 
to public prices and costs to SSI. The 
prices of these drugs vary between 9.04 
TL (Oxofen 2 mg/ml 150 ml with active 
substance fenspiride hydrochloride) and 
16.226,00 TL (Imbruvica 140 mg 120 
capsules with ibrutinib active substance), 
but the average public price is 3.839.67 
TL.
When the average of the reference 
prices of products purchased with an 
alternative reimbursement method are 
considered, the overall average was 
3.167,00 €. An examination of the yearly 
average reveals that the average price 
was very high in 2016. This can be ex-
plained by the fact that the price of three 
of the seven products purchased in 2016 
was over € 8.000.00. In 2017, nine prod-
ucts were covered, and the price of five 
of the products was under € 1,000,00. 
In 2018, 18 medicines and 29 products 
were purchased, and 12 of these products 
cost between 3.000,00 and 8.000,00 €. In 
2019, a product (Pralidoxime Methylsul-
fate – Contrathion) was added to the List 
of Reimbursed Medicines for 4A, and 
the reference price of the product was € 
40.50 (Table III).
An examination of the list prices also 
revealed that the highest general average 
was for 2017. The reason for this is that 
the list price of the drug named Spinraza 
(active ingredient nusinersen) added to 
the 4C International Drug Price List in 
2017 and included in the reimbursement 
list was 90.000,00 €.
There was no statistically signifi-
cant difference between the average list 
price (Turkish Lira-TL) and the refer-








Non-Small Cell Lung Cancer 3
Multiple Myeloma and Plasma Cell Disorders (Rare Disease) 3
Phenylketonuria (Rare Disease) 2
MPS (Maroteaux-Lamy) Type VI (Rare Disease) 1
Chronic Lymphocytic Leukemia 1
Diabetic Foot Ulcer 1
Leptin Deficiency (Rare Disease) 1
Respiratory Inflammation 1
Bile Acid Synthesis Disorders and Zellweger Spectrum Disorders 
(Rare Disease)
1
Duchenne Muscular Dystrophy (DMD) (Rare Disease) 1
Osteosarcoma 1
Ulcerative Colitis and Crohn's Disease 1
Morquio Syndrome (Rare Disease) 1
Spinal Muscular Atrophy (SMA) (Rare Disease) 1
Gaucher's Disease (Rare Disease) 1
Acute Lymphocytic Leukemia (ALL) 1
Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic 
Uremic Syndrome (Rare Drug)
1
Parkinson's Disease 1





Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma (Rare 
Disease)
1
Acute and Chronic Leukemia (Rare Disease) 1
AIDS with Cytomegalovirus (CMV) Retinitis 1
Brain Tumors, Multiple Myeloma, Hodgkin's Disease, Non-Hodgkin's 
Lymphoma
1
Medullary Thyroid Cancer (Rare Disease) 1
Eczema 1
Hunter Syndrome 1
Leishmaniosis, Free Living Amoeba Infections 1
Hypertriglyceridemia 1
Cancer, Wilson's Disease, Copper Metabolism Disorders: 
Seropositive Rheumatoid Arthritis, Rheumatoid Arthritis, other; 
Juvenile Arthritis, Amino-acid Transport Disorders
1
Congenital Metabolic and Hereditary Diseases 1
MNGIE (Mitochondrial Neurogastrointestinal Encephalomyelopathy), 
Congenital Metabolic and Hereditary Diseases
1
Organic Phosphorus Insecticide and Chemical Composition 
Poisoning
1
Table II. Alternative Reimbursement Drugs by disease
Figure 2. Reimbursement discount rates of drugs covered by alternative 
reimbursement
General 2016 2017 2018 2019
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Table III. Average Reference and List Prices of Drugs Covered by Alternative Reimbursement
List prices of the products in the 4A Reimbursed Medicines List issued by the SSI are given in Turkish Lira and the list price of the products in 4C 
International Drug Price List is given in Euro. To make comparisons, the prices of the products in the rate of 1 Euro = 6,67 TL and 4C International Drug 
Price List dated 06.05.2019 are calculated as 1 Euro = 1.11 Dollars.
Reference Prices include the list of Reimbursed Medicines for 4A.
The reference prices of the products listed in the 4A Reimbursed Medicines List are given in Euros. The conversion of these products as per the 
“Pharmaceutical Industry Association of Turkey” published by the “Applied Periodic Euro Value of Drug Price (DAD)” is calculated over. As of 14.02.2019, 
the fixed exchange rate to be applied for drugs is 3.4037
SD = standard deviation
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the list price of the drug named Spinraza 
(active ingredient nusinersen) added to 
the 4C International Drug Price List in 
2017 and included in the reimbursement 
list was 90.000,00 €.
There was no statistically signifi-
cant difference between the average list 
price (Turkish Lira-TL) and the refer-








Non-Small Cell Lung Cancer 3
Multiple Myeloma and Plasma Cell Disorders (Rare Disease) 3
Phenylketonuria (Rare Disease) 2
MPS (Maroteaux-Lamy) Type VI (Rare Disease) 1
Chronic Lymphocytic Leukemia 1
Diabetic Foot Ulcer 1
Leptin Deficiency (Rare Disease) 1
Respiratory Inflammation 1
Bile Acid Synthesis Disorders and Zellweger Spectrum Disorders 
(Rare Disease)
1
Duchenne Muscular Dystrophy (DMD) (Rare Disease) 1
Osteosarcoma 1
Ulcerative Colitis and Crohn's Disease 1
Morquio Syndrome (Rare Disease) 1
Spinal Muscular Atrophy (SMA) (Rare Disease) 1
Gaucher's Disease (Rare Disease) 1
Acute Lymphocytic Leukemia (ALL) 1
Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic 
Uremic Syndrome (Rare Drug)
1
Parkinson's Disease 1





Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma (Rare 
Disease)
1
Acute and Chronic Leukemia (Rare Disease) 1
AIDS with Cytomegalovirus (CMV) Retinitis 1
Brain Tumors, Multiple Myeloma, Hodgkin's Disease, Non-Hodgkin's 
Lymphoma
1
Medullary Thyroid Cancer (Rare Disease) 1
Eczema 1
Hunter Syndrome 1
Leishmaniosis, Free Living Amoeba Infections 1
Hypertriglyceridemia 1
Cancer, Wilson's Disease, Copper Metabolism Disorders: 
Seropositive Rheumatoid Arthritis, Rheumatoid Arthritis, other; 
Juvenile Arthritis, Amino-acid Transport Disorders
1
Congenital Metabolic and Hereditary Diseases 1
MNGIE (Mitochondrial Neurogastrointestinal Encephalomyelopathy), 
Congenital Metabolic and Hereditary Diseases
1
Organic Phosphorus Insecticide and Chemical Composition 
Poisoning
1
Table II. Alternative Reimbursement Drugs by disease
Figure 2. Reimbursement discount rates of drugs covered by alternative 
reimbursement
General 2016 2017 2018 2019
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Table III. Average Reference and List Prices of Drugs Covered by Alternative Reimbursement
List prices of the products in the 4A Reimbursed Medicines List issued by the SSI are given in Turkish Lira and the list price of the products in 4C 
International Drug Price List is given in Euro. To make comparisons, the prices of the products in the rate of 1 Euro = 6,67 TL and 4C International Drug 
Price List dated 06.05.2019 are calculated as 1 Euro = 1.11 Dollars.
Reference Prices include the list of Reimbursed Medicines for 4A.
The reference prices of the products listed in the 4A Reimbursed Medicines List are given in Euros. The conversion of these products as per the 
“Pharmaceutical Industry Association of Turkey” published by the “Applied Periodic Euro Value of Drug Price (DAD)” is calculated over. As of 14.02.2019, 
the fixed exchange rate to be applied for drugs is 3.4037
SD = standard deviation
the average fixed exchange rate of the drugs 
included in the List of Reimbursed Medi-
cines in Annex-4A (p=0.271). There was no 
significant difference between the average 
list price (€) of the drugs in the List of Reim-
bursed Medicines in Annex-4A and the aver-
age list price (€) of the drugs in the Annex-4C 
International Drug Price List (p=0.169). On a 
year-by-year basis, there was no statistically 
significant difference between the average 
list price (TL) of the drugs included in the 
List of Reimbursed Medicines for Annex-4A 
in 2016 and the reference price (TL) calcu-
lated according to the average fixed rate of 
2016 (p=0.290). Furthermore, no significant 
difference was detected between the aver-
age list price (€) of the drugs included in the 
List of Reimbursed Medicines in Annex-4A 
in 2016 and the average list price (€) of the 
drugs included in the Annex-4C International Drug Price List in 2016 (p=0.320). However, a 
significant difference between the average list price (TL) of drugs included in the List of Re-
imbursed Medicines for Annex-4A in 2017 and the reference price (TL) calculated according 
to the 2017 average fixed rate (p=0.015) was detected. Furthermore, a significant difference 
between the average list price (€) of the drugs included in the List of Reimbursed Medicines 
in Annex-4A in 2017 and the average list price (€) of the drugs included in the Annex-4C In-
ternational Drug Price List in 2017 (p=0.177) was found. Results also revealed no significant 
difference between the average list price (TL) of the drugs included in the List of Reimbursed 
Medicines in Annex-4A Price (TL) and the reference price (TL) calculated according to the 
2018 average fixed exchange rate (p=0.169). Furthermore, there was no significant difference 
between the average list price (€) of the drugs included in the List of Reimbursed Medicines 
in Annex-4A in 2018 and the average list price (€) of the drugs included in the Annex-4C 
International Drug Price List in 2018 (p=0.222).
The most involved pharmaceutical companies in the alternative reimbursement process 
were Roche, with five drugs, and Abbvie, Biomarin, Gilead, and Takeda with three drugs 
each. In countries where the prices of the drugs included in the List of Reimbursed Medicines 
for 4A and the alternative reimbursement process are taken as a reference, Switzerland is fol-
lowed by Greece.
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DISCUSSION
ARC, which was established in line with the regulation issued in 2016, aims to keep 
pharmaceutical expenditures under control and to deliver the needed treatment to patients at 
a lower cost with the agreements made between the pharmaceutical companies and the reim-
bursement institution. In general, alternative reimbursement models are preferred to ensure 
the reimbursement of high-cost drugs.
In practice, since Turkey launched several drugs that were included in the scope of reim-
bursement, alternative methods of reimbursement have increased every year. It was found 
that most of the drugs had been added to the List of Reimbursement Medicines for Annex 4A.
Most of the drugs added to the List of Reimbursement Medicines are regarded as original 
drugs. This is an indication of the need for reimbursement in new and effective treatments. 
It could be said that drugs that are added to the list for alternative reimbursement are usually 
related to oncology and immune system diseases. Due to the high cost of oncology medicine, 
oncology medicines are mostly included in ARC for controlling the possible budget impact.
Within the scope of alternative reimbursement, approximately 80% of the drugs added to 
the List of Reimbursement Medicines for 4A and the List of 4C International Medicines had 
confidential discounts applied. The purpose of the confidential discount in alternative reim-
bursement methods is to reach the same public price with higher discounts instead of decreas-
ing the sales price to the warehouse, excluding value added tax (VAT). In this manner, price 
flexibility is provided, and the market availability of medicines is ensured. Furthermore, the 
budgetary impact of high-cost drugs on the SSI is reduced by the use of confidential discounts.
CONCLUSIONS
Market access agreements, named as alternative reimbursement models, in Turkey are 
beneficial for both reimbursement institutions and pharmaceutical companies. The agree-
ments provide additional discounts for reimbursement institutions and set fixed prices for 
pharmaceutical companies over the term of the agreement. These study findings are unique in 
literature and may help decision-makers and companies for their future planning for market 
access of innovative medicines.
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